Guide to using AAV vectors in gene therapy
Drug Discovery World
FEBRUARY 8, 2024
Dr O’Hara began by recognising the challenges associated with AAV therapeutic development, e.g., how plasmids are difficult to synthesize, amplify, and analyse with standard molecular biology protocols. Questions were fielded from the audience, which included: What analysis will be performed to evaluate host or other DNA contamination?
Let's personalize your content